{
    "evidence": [
        {
            "id": 2997,
            "name": "EID2997",
            "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
            "disease": {
                "id": 8,
                "name": "Lung Non-small Cell Carcinoma",
                "display_name": "Lung Non-small Cell Carcinoma",
                "doid": 3908,
                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
            },
            "drugs": [
                {
                    "id": 146,
                    "name": "Afatinib",
                    "ncit_id": "C66940",
                    "aliases": [
                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                        "BIBW 2992",
                        "BIBW2992"
                    ]
                }
            ],
            "rating": 5,
            "evidence_level": "A",
            "evidence_type": "PREDICTIVE",
            "clinical_significance": "SENSITIVITYRESPONSE",
            "evidence_direction": "SUPPORTS",
            "variant_origin": "SOMATIC",
            "drug_interaction_type": null,
            "status": "accepted",
            "type": "evidence",
            "source": {
                "id": 1725,
                "name": "Afatinib: first global approval.",
                "citation": "Dungo et al., 2013, Drugs",
                "citation_id": 23982599,
                "source_type": "PUBMED",
                "asco_abstract_id": null,
                "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
                "pmc_id": null,
                "publication_date": "2013-9",
                "journal": "Drugs",
                "full_journal_title": "Drugs",
                "clinical_trials": []
            },
            "variant_id": 33,
            "phenotypes": [],
            "assertions": [
                {
                    "id": 6,
                    "type": "assertion",
                    "name": "AID6",
                    "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                    "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                    "gene_id": 19,
                    "variant_id": 33,
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "evidence_type": "PREDICTIVE",
                    "evidence_direction": "SUPPORTS",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "fda_regulatory_approval": true,
                    "status": "accepted"
                }
            ],
            "gene_id": 19
        }
    ],
    "assertions": [
        {
            "id": 6,
            "type": "assertion",
            "name": "AID6",
            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
            "gene_id": 19,
            "variant_id": 33,
            "disease": {
                "id": 8,
                "name": "Lung Non-small Cell Carcinoma",
                "display_name": "Lung Non-small Cell Carcinoma",
                "doid": 3908,
                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
            },
            "drugs": [
                {
                    "id": 146,
                    "name": "Afatinib",
                    "ncit_id": "C66940",
                    "aliases": [
                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                        "BIBW 2992",
                        "BIBW2992"
                    ]
                }
            ],
            "evidence_type": "PREDICTIVE",
            "evidence_direction": "SUPPORTS",
            "clinical_significance": "SENSITIVITYRESPONSE",
            "fda_regulatory_approval": true,
            "status": "accepted",
            "nccn_guideline": {
                "name": "Non-Small Cell Lung Cancer"
            },
            "nccn_guideline_version": "3.2018",
            "amp_level": "TIER_I_LEVEL_A",
            "evidence_items": [
                {
                    "id": 2997,
                    "name": "EID2997",
                    "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 5,
                    "evidence_level": "A",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1725,
                        "name": "Afatinib: first global approval.",
                        "citation": "Dungo et al., 2013, Drugs",
                        "citation_id": 23982599,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
                        "pmc_id": null,
                        "publication_date": "2013-9",
                        "journal": "Drugs",
                        "full_journal_title": "Drugs",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                },
                {
                    "id": 879,
                    "name": "EID879",
                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 592,
                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
                        "citation_id": 23816960,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
                        "pmc_id": null,
                        "publication_date": "2013-9-20",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                },
                {
                    "id": 982,
                    "name": "EID982",
                    "description": "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 679,
                        "name": "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.",
                        "citation": "Wu et al., 2014, Lancet Oncol.",
                        "citation_id": 24439929,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24439929",
                        "pmc_id": null,
                        "publication_date": "2014-2",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                },
                {
                    "id": 883,
                    "name": "EID883",
                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 594,
                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
                        "citation": "Yang et al., 2012, Lancet Oncol.",
                        "citation_id": 22452895,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
                        "pmc_id": null,
                        "publication_date": "2012-5",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                },
                {
                    "id": 968,
                    "name": "EID968",
                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 669,
                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
                        "citation": "Hirano et al., 2015, Oncotarget",
                        "citation_id": 26515464,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
                        "pmc_id": "PMC4770737",
                        "publication_date": "2015-11-17",
                        "journal": "Oncotarget",
                        "full_journal_title": "Oncotarget",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                },
                {
                    "id": 2629,
                    "name": "EID2629",
                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1525,
                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
                        "citation": "Li et al., 2008, Oncogene",
                        "citation_id": 18408761,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
                        "pmc_id": "PMC2748240",
                        "publication_date": "2008-8-7",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": [],
                    "assertions": [
                        {
                            "id": 6,
                            "type": "assertion",
                            "name": "AID6",
                            "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                            "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                            "gene_id": 19,
                            "variant_id": 33,
                            "disease": {
                                "id": 8,
                                "name": "Lung Non-small Cell Carcinoma",
                                "display_name": "Lung Non-small Cell Carcinoma",
                                "doid": 3908,
                                "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                            },
                            "drugs": [
                                {
                                    "id": 146,
                                    "name": "Afatinib",
                                    "ncit_id": "C66940",
                                    "aliases": [
                                        "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                        "BIBW 2992",
                                        "BIBW2992"
                                    ]
                                }
                            ],
                            "evidence_type": "PREDICTIVE",
                            "evidence_direction": "SUPPORTS",
                            "clinical_significance": "SENSITIVITYRESPONSE",
                            "fda_regulatory_approval": true,
                            "status": "accepted"
                        }
                    ],
                    "gene_id": 19
                }
            ],
            "acmg_codes": [],
            "drug_interaction_type": null,
            "fda_companion_test": true,
            "phenotypes": [],
            "variant_origin": "SOMATIC"
        }
    ],
    "genes": [
        {
            "id": 19,
            "name": "EGFR",
            "entrez_id": 1956,
            "description": "EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).",
            "variants": [
                {
                    "name": "3' UTR MUTATION",
                    "id": 253,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 1,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "A289V",
                    "id": 996,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "A702S",
                    "id": 2255,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "A750T",
                    "id": 2332,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "A763_Y764insFQEA",
                    "id": 1515,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "A767_V769dupASV",
                    "id": 1579,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "A859T",
                    "id": 1474,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "A864T",
                    "id": 1187,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "AUTOCRINE ACTIVATION",
                    "id": 309,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 2,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Amplification",
                    "id": 190,
                    "evidence_items": {
                        "accepted_count": 11,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "C797G",
                    "id": 3003,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "C797S",
                    "id": 415,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 6
                    }
                },
                {
                    "name": "C797Y",
                    "id": 1574,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Copy Number Variation",
                    "id": 191,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D761N",
                    "id": 1013,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "D761Y",
                    "id": 712,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D770_N771insG",
                    "id": 1512,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "D770_N771insGL",
                    "id": 1514,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D770_N771insGT",
                    "id": 1566,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "D770_N771insNPG",
                    "id": 1569,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "D770_N771insSVD",
                    "id": 1445,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "D770delinsGY",
                    "id": 2214,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 1,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "E114K",
                    "id": 3464,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "E709A and G719C",
                    "id": 2258,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E709K",
                    "id": 1412,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "E709K and G719A",
                    "id": 2256,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E709Q",
                    "id": 1413,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E709_T710>D",
                    "id": 1577,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "E734Q",
                    "id": 1572,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "E746G",
                    "id": 724,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "E746K",
                    "id": 1431,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E746V",
                    "id": 1005,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 6
                    }
                },
                {
                    "name": "E746_A750>IP",
                    "id": 1635,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E746_A750del",
                    "id": 1002,
                    "evidence_items": {
                        "accepted_count": 3,
                        "rejected_count": 0,
                        "submitted_count": 19
                    }
                },
                {
                    "name": "E746_S752>A",
                    "id": 1433,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E746_S752delinsD",
                    "id": 1009,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "E746_T751>I",
                    "id": 1003,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 6
                    }
                },
                {
                    "name": "E746_T751delinsA",
                    "id": 1004,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "E746_T751delinsVA",
                    "id": 1214,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "E868G",
                    "id": 1482,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "E884K",
                    "id": 1390,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "EGFR::RAD51",
                    "id": 2203,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Ex19 del L858R",
                    "id": 1854,
                    "evidence_items": {
                        "accepted_count": 3,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Exon 18 Overexpression",
                    "id": 375,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Exon 18 deletion",
                    "id": 2257,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Exon 19 Deletion",
                    "id": 133,
                    "evidence_items": {
                        "accepted_count": 16,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "Exon 20 Insertion",
                    "id": 726,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "Exon 4 Deletion",
                    "id": 252,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Expression",
                    "id": 354,
                    "evidence_items": {
                        "accepted_count": 5,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "F404I",
                    "id": 2616,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "F404V",
                    "id": 2617,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G465E",
                    "id": 2603,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G465R",
                    "id": 443,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G465V",
                    "id": 2604,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G598V",
                    "id": 997,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 6
                    }
                },
                {
                    "name": "G63R",
                    "id": 3488,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "G719",
                    "id": 718,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "G719A",
                    "id": 999,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "G719D",
                    "id": 1420,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "G719S",
                    "id": 134,
                    "evidence_items": {
                        "accepted_count": 4,
                        "rejected_count": 0,
                        "submitted_count": 7
                    }
                },
                {
                    "name": "G724S",
                    "id": 317,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "G810S",
                    "id": 1016,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "Gain-of-function",
                    "id": 1765,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "H773_V774insH",
                    "id": 1446,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "H773_V774insNPH",
                    "id": 1513,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "I462K",
                    "id": 2599,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "I462R",
                    "id": 2600,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "I491K",
                    "id": 2608,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "I491R",
                    "id": 2609,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "I744_K745insKIPVAI",
                    "id": 2259,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K467N",
                    "id": 2605,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K467T",
                    "id": 455,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K489E",
                    "id": 2607,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K489Q",
                    "id": 2606,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K708R",
                    "id": 3490,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "K745_E749delKELRE",
                    "id": 1638,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "K757R",
                    "id": 723,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "K806E",
                    "id": 1895,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L718Q",
                    "id": 2999,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "L718V",
                    "id": 3000,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "L718V and L718Q",
                    "id": 2997,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "L747P",
                    "id": 1891,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L747_A750>P",
                    "id": 1006,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "L747_P753>Q",
                    "id": 1011,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "L747_P753delinsS",
                    "id": 1012,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 8
                    }
                },
                {
                    "name": "L747_S752del",
                    "id": 890,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 7
                    }
                },
                {
                    "name": "L747_S752delinsQ",
                    "id": 1580,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L747_T751delLREAT",
                    "id": 1007,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "L747_T751delinsP",
                    "id": 1010,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 6
                    }
                },
                {
                    "name": "L747_T751delinsQ",
                    "id": 1008,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "L792H",
                    "id": 3004,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "L838P",
                    "id": 1457,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L838V",
                    "id": 1018,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L858Q",
                    "id": 1473,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "L858R",
                    "id": 33,
                    "evidence_items": {
                        "accepted_count": 36,
                        "rejected_count": 1,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "L861",
                    "id": 1866,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "L861Q",
                    "id": 1020,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "L861R",
                    "id": 1477,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "M766Q",
                    "id": 2745,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "M766_A767insAI",
                    "id": 1664,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "M766_A767insASV",
                    "id": 2213,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Mutation",
                    "id": 442,
                    "evidence_items": {
                        "accepted_count": 16,
                        "rejected_count": 1,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "N771>GY",
                    "id": 1581,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "N771_P772insL",
                    "id": 3304,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "N771delinsVH",
                    "id": 1662,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "N826S",
                    "id": 1188,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "N826Y",
                    "id": 1896,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "N842S",
                    "id": 1899,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Overexpression",
                    "id": 193,
                    "evidence_items": {
                        "accepted_count": 9,
                        "rejected_count": 2,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "P546S",
                    "id": 1582,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "P596L",
                    "id": 3489,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "P753S",
                    "id": 460,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "P772_H773insH",
                    "id": 2217,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "P772_H773insYNP",
                    "id": 1667,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "P772_V774insPHV",
                    "id": 1668,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "P848L",
                    "id": 1465,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "R108K",
                    "id": 994,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "R165Q",
                    "id": 3470,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "R222C",
                    "id": 3344,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "R252C",
                    "id": 3961,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "R451C",
                    "id": 454,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "R705K",
                    "id": 2333,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "R776C",
                    "id": 1181,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "R831H",
                    "id": 1017,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 3
                    }
                },
                {
                    "name": "R832L",
                    "id": 2741,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "Rare Exon 18-21 Mutation",
                    "id": 1863,
                    "evidence_items": {
                        "accepted_count": 2,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Rare Mutation",
                    "id": 2334,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "S442I",
                    "id": 2615,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S442R",
                    "id": 2614,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S464L",
                    "id": 2601,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S464T",
                    "id": 2602,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S492C",
                    "id": 2610,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S492R",
                    "id": 453,
                    "evidence_items": {
                        "accepted_count": 4,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "S720",
                    "id": 720,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "S752_I759delSPKANKEI",
                    "id": 891,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "S768I",
                    "id": 562,
                    "evidence_items": {
                        "accepted_count": 5,
                        "rejected_count": 0,
                        "submitted_count": 5
                    }
                },
                {
                    "name": "S768N",
                    "id": 1443,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "S768_D770dup",
                    "id": 1511,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "S784F",
                    "id": 1182,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 4
                    }
                },
                {
                    "name": "T263P",
                    "id": 995,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "T415M",
                    "id": 2618,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "T725M",
                    "id": 861,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "T785A",
                    "id": 1573,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "T790M",
                    "id": 34,
                    "evidence_items": {
                        "accepted_count": 31,
                        "rejected_count": 2,
                        "submitted_count": 9
                    }
                },
                {
                    "name": "T847I",
                    "id": 1463,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "T854A",
                    "id": 1467,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "V441D",
                    "id": 2612,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "V441F",
                    "id": 2613,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V441G",
                    "id": 2611,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "V742A",
                    "id": 1001,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "V769A",
                    "id": 1578,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "V769_D770insASV",
                    "id": 736,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "V774A",
                    "id": 1892,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V774M",
                    "id": 1894,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V774_C775insHV",
                    "id": 1567,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "V834I",
                    "id": 1897,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "V851I",
                    "id": 1466,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "VIII",
                    "id": 312,
                    "evidence_items": {
                        "accepted_count": 7,
                        "rejected_count": 0,
                        "submitted_count": 2
                    }
                },
                {
                    "name": "W731L",
                    "id": 1571,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Wildtype",
                    "id": 2174,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 1,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Y1092 PHOSPHORYLATION",
                    "id": 390,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                },
                {
                    "name": "Y69FS*11",
                    "id": 1672,
                    "evidence_items": {
                        "accepted_count": 0,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Y764_V765insHH",
                    "id": 1665,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 1
                    }
                },
                {
                    "name": "Y801H",
                    "id": 1575,
                    "evidence_items": {
                        "accepted_count": 1,
                        "rejected_count": 0,
                        "submitted_count": 0
                    }
                }
            ],
            "aliases": [
                "EGFR",
                "ERBB",
                "ERBB1",
                "ERRP",
                "HER1",
                "NISBD2",
                "PIG61",
                "mENA"
            ],
            "type": "gene"
        }
    ],
    "variants": [
        {
            "id": 33,
            "entrez_name": "EGFR",
            "entrez_id": 1956,
            "name": "L858R",
            "description": "EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.",
            "gene_id": 19,
            "type": "variant",
            "variant_types": [
                {
                    "id": 47,
                    "name": "Missense Variant",
                    "so_id": "SO:0001583",
                    "description": "A sequence variant, that changes one or more bases, resulting in a different amino acid sequence but where the length is preserved.",
                    "url": "http://www.sequenceontology.org/browser/current_svn/term/SO:0001583"
                }
            ],
            "civic_actionability_score": 375,
            "coordinates": {
                "chromosome": "7",
                "start": 55259515,
                "stop": 55259515,
                "reference_bases": "T",
                "variant_bases": "G",
                "representative_transcript": "ENST00000275493.2",
                "chromosome2": null,
                "start2": null,
                "stop2": null,
                "representative_transcript2": null,
                "ensembl_version": 75,
                "reference_build": "GRCh37"
            },
            "evidence_items": [
                {
                    "id": 2994,
                    "name": "EID2994",
                    "description": "On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 5,
                    "evidence_level": "A",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1724,
                        "name": "U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.",
                        "citation": "Khozin et al., 2014, Oncologist",
                        "citation_id": 24868098,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24868098",
                        "pmc_id": "PMC4077454",
                        "publication_date": "2014-7",
                        "journal": "Oncologist",
                        "full_journal_title": "The oncologist",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2997,
                    "name": "EID2997",
                    "description": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 5,
                    "evidence_level": "A",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1725,
                        "name": "Afatinib: first global approval.",
                        "citation": "Dungo et al., 2013, Drugs",
                        "citation_id": 23982599,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23982599",
                        "pmc_id": null,
                        "publication_date": "2013-9",
                        "journal": "Drugs",
                        "full_journal_title": "Drugs",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4860,
                    "name": "EID4860",
                    "description": "The authors pooled patients with exon 19 deletion and L858R EGFR (Exon 21) mutations from both studies (The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067)) to compare the efficacy of dacomitinib to erlotinib. 121 patients with any EGFR mutation were enrolled, 101 had activating mutations in exon 19 or 21. For those (exon19/21), the median PFS was 14.6 months with dacomitinib and 9.6 months with erlotinib The median survival was 26.6 months with dacomitinib versus 23.2 months with erlotinib.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 44,
                            "name": "Dacomitinib",
                            "ncit_id": "C53398",
                            "aliases": [
                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
                                "EGFR Inhibitor PF-00299804",
                                "PF-00299804",
                                "PF-00299804-03",
                                "PF-299804",
                                "Vizimpro"
                            ]
                        }
                    ],
                    "rating": 5,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2158,
                        "name": "Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.",
                        "citation": "Ramalingam et al., 2016, Ann. Oncol.",
                        "citation_id": 26768165,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26768165",
                        "pmc_id": null,
                        "publication_date": "2016-3",
                        "journal": "Ann. Oncol.",
                        "full_journal_title": "Annals of oncology : official journal of the European Society for Medical Oncology",
                        "clinical_trials": [
                            {},
                            {},
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 275,
                    "name": "EID275",
                    "description": "In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        },
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": "SUBSTITUTES",
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 182,
                        "name": "Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.",
                        "citation": "Fukihara et al., 2014, Oncology",
                        "citation_id": 24457318,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24457318",
                        "pmc_id": null,
                        "publication_date": "2014",
                        "journal": "Oncology",
                        "full_journal_title": "Oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 879,
                    "name": "EID879",
                    "description": "A phase III clinical trial (NCT00949650) found that median progression free survival among patients with exon 19 deletions or L858R EGFR mutations (n = 308) was 13.6 months for afatinib and 6.9 months for chemotherapy (HR, 0.47; 95% CI, 0.34 to 0.65; P = 0.001).",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 592,
                        "name": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
                        "citation": "Sequist et al., 2013, J. Clin. Oncol.",
                        "citation_id": 23816960,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/23816960",
                        "pmc_id": null,
                        "publication_date": "2013-9-20",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 982,
                    "name": "EID982",
                    "description": "Afatinib is an irreversible covalent inhibitor of EGFR (second generation). This Phase III clinical trial (LUX-Lung 6; NCT01121393) was performed in Asian patients with EGFR mutant advanced NSCLC. 364 eligible patients with EGFR mutations were assigned to afatinib (n=242) or gemcitabine and cisplatin (n=122) treatment. The trial observed significantly longer median progression-free survival with afatinib vs. gemcitabine and cisplatin treatment (11.0 vs. 5.6 months). Afatinib/Chemotherapy group compositions: 51.2/50.8 % del 19; 38/37.7 % Leu858Arg; 10.8/11.5 % Uncommon.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 679,
                        "name": "Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.",
                        "citation": "Wu et al., 2014, Lancet Oncol.",
                        "citation_id": 24439929,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24439929",
                        "pmc_id": null,
                        "publication_date": "2014-2",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2621,
                    "name": "EID2621",
                    "description": "In a phase 3 clinical trial of non-small cell lung cancer (NSCLC) patients, a subset of patients with EGFR mutations (n=44) treated with gefitinib were associated with improved progression free survival (HR: 0.16, 95% CI: 0.05-0.49, P=0.001), and a higher objective response rate (ORR: 42.1% vs 21.1%, p=0.04) compared to patients treated with docetaxel. Of the 44 patients, 22 had an exon 19 deletion, 16 had an L858R mutation, one patient had an exon 20 T790M mutation, two had an exon G719A mutation and four had other mutations.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1501,
                        "name": "Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.",
                        "citation": "Douillard et al., 2010, J. Clin. Oncol.",
                        "citation_id": 20038723,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20038723",
                        "pmc_id": null,
                        "publication_date": "2010-2-10",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 229,
                    "name": "EID229",
                    "description": "There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib with EGFR L858R mutations (N=72/242; univariate: P=0.283; multivariate: P=0.250) compared to patients with Exon 19 mutations (N=170).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        },
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": "SUBSTITUTES",
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 162,
                        "name": "Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.",
                        "citation": "Lim et al., 2014, J Thorac Oncol",
                        "citation_id": 24736073,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24736073",
                        "pmc_id": null,
                        "publication_date": "2014-4",
                        "journal": "J Thorac Oncol",
                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 347,
                    "name": "EID347",
                    "description": "Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PROGNOSTIC",
                    "clinical_significance": "BETTER_OUTCOME",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 213,
                        "name": "Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.",
                        "citation": "Douillard et al., 2014, J Thorac Oncol",
                        "citation_id": 24662454,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24662454",
                        "pmc_id": null,
                        "publication_date": "2014-5",
                        "journal": "J Thorac Oncol",
                        "full_journal_title": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 883,
                    "name": "EID883",
                    "description": "In a phase 2 study of patients with lung adenocarcinoma (stage IIIb with pleural effusion or stage IV) and EGFR mutations, treated with afatinib were assessed by objective response. 129 patients were treated with afatinib. 66% of the 106 patients with two common activating EGFR mutations (deletion 19 or L858R) had an objective response compared to 39% of 23 patients with less common mutations.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 594,
                        "name": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
                        "citation": "Yang et al., 2012, Lancet Oncol.",
                        "citation_id": 22452895,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452895",
                        "pmc_id": null,
                        "publication_date": "2012-5",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 885,
                    "name": "EID885",
                    "description": "A randomized phase 3 trial (NCT00446225) involving 173 NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease. Patients were randomly allocated (1:1) to receive either erlotinib or standard chemotherapy. The primary endpoint was progression-free survival (PFS). Median PFS was 9.7 months in the erlotinib group, compared with 5.2 months in the standard chemotherapy group.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 595,
                        "name": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
                        "citation": "Rosell et al., 2012, Lancet Oncol.",
                        "citation_id": 22285168,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22285168",
                        "pmc_id": null,
                        "publication_date": "2012-3",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 1665,
                    "name": "EID1665",
                    "description": "90 NSCLC patients with stage IIIB/IV chemotherapy-resistant tumors were treated with gefitinib, and the L858R EGFR mutation was associated with longer time to treatment failure than those with wild-type EGFR (median 9.1 versus 2.1). In multivariate analysis, L858R mutations plus adenocarcinoma was a significant predictive factor for time to treatment failure (HR = 0.1030; P = .0004).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1127,
                        "name": "Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.",
                        "citation": "Yang et al., 2008, J. Clin. Oncol.",
                        "citation_id": 18509184,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18509184",
                        "pmc_id": null,
                        "publication_date": "2008-6-1",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2634,
                    "name": "EID2634",
                    "description": "In a phase 3 clinical trial of Korean, never-smoker, lung adenocarcinoma patients, a subset of patients with EGFR mutations (n=42) treated with gefitinib were associated with improved overall response rate compared to gemcitabine plus cisplatin treatment (84.6%, 22/26, vs. 37.5%, 6/16, P=0.002). By contrast, in EGFR mutation negative cases, the response rate was much lower (25.9%, 7/27). The frequency of mutation in exon 19 deletion and L858R was 64.3% (27/42) and 36.4% (16/42), respectively. Exon 19 and L858R mutations were mutually exclusive in this cohort.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1513,
                        "name": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.",
                        "citation": "Han et al., 2012, J. Clin. Oncol.",
                        "citation_id": 22370314,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22370314",
                        "pmc_id": null,
                        "publication_date": "2012-4-1",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4290,
                    "name": "EID4290",
                    "description": "In a prospective study of 46 Caucasian, advanced lung adenocarcinoma patients harboring EGFR mutations, first-line erlotinib treatment was assessed. Average PFS and OS for these 46 patients was 11 months (95% CI: 9.7-12.3 months) and 23 months (95% CI: 21.3-28.6+ months), respectively. A PFS rate of 81% at three months met the primary endpoint of presumed superiority over chemotherapy. Clinical benefit (CR+PR+SD) rate was 81%. Fifteen patients harbored EGFR L858R mutations, which was the only mutation found in exon 21. The authors note similar response profiles for exon 19 (27/46) and exon 21 mutations (15/46) to the overall population.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2067,
                        "name": "Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT).",
                        "citation": "De Gr\u00e8ve et al., 2016, PLoS ONE",
                        "citation_id": 27032107,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27032107",
                        "pmc_id": "PMC4816447",
                        "publication_date": "2016",
                        "journal": "PLoS ONE",
                        "full_journal_title": "PloS one",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 6183,
                    "name": "EID6183",
                    "description": "In a Japanese Phase III clinical trial, noninferiority of Gefitinib as compared to Erlotinib was assessed in 561 postoperative recurrent or stage IIIb/VI patients who had undergone prior chemotherapy treatment but no tyrosine kinase inhibitor therapy. In a subset of patients with sole EGFR L858R, there was an insignificant difference between the objective response and disease control rates for patients treated with erlotinib (N=67) and gefitinib (N=78). Progression free survival was also not significantly different and did not meet the noninferiority endpoint with Gefitinib and Erlotinib arms at 8.1 and 8.5 months, respectively (HR, 0.938; 95% CI, 0.675 to 1.304; P = .704).",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "B",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2478,
                        "name": "Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.",
                        "citation": "Urata et al., 2016, J. Clin. Oncol.",
                        "citation_id": 27022112,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27022112",
                        "pmc_id": null,
                        "publication_date": "2016",
                        "journal": "J. Clin. Oncol.",
                        "full_journal_title": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2623,
                    "name": "EID2623",
                    "description": "In a phase 3 clinical trial of Japanese NSCLC patients with EGFR mutations (n=230), patients treated with gefitinib were associated with improved progression free survival (10.8 months vs 5.4 months, HR: 0.30, 95% CI: 0.22-0.41, P<0.001), compared to patients treated with carboplatin and paclitaxel combination therapy. The frequency of mutation of exon 19 deletion and L858R was 25.2% (58/230) and 21.3% (49/230), respectively.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 1508,
                        "name": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.",
                        "citation": "Maemondo et al., 2010, N. Engl. J. Med.",
                        "citation_id": 20573926,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20573926",
                        "pmc_id": null,
                        "publication_date": "2010-6-24",
                        "journal": "N. Engl. J. Med.",
                        "full_journal_title": "The New England journal of medicine",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2630,
                    "name": "EID2630",
                    "description": "In a phase 2b/3 study of 585 stage IIIB-IV lung adenocarcinoma patients who had a previous round of EGFR-TKI treatment, archival material was available for 141 patients. EGFR mutational analysis revealed that 96 tumors had an EGFR mutation, of which 76 (79%) were positive for either L858R or a deletion in exon 19. These mutations were associated with improved progression-free survival (median 3.3 months  vs 1.0 month ; HR:0.51, 95% CI:0.31-0.85, P<0.009) compared to placebo control.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": null,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 1510,
                        "name": "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.",
                        "citation": "Miller et al., 2012, Lancet Oncol.",
                        "citation_id": 22452896,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22452896",
                        "pmc_id": null,
                        "publication_date": "2012-5",
                        "journal": "Lancet Oncol.",
                        "full_journal_title": "The Lancet. Oncology",
                        "clinical_trials": [
                            {}
                        ]
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 8053,
                    "name": "EID8053",
                    "description": "A 62 year old patient with 4 pack-year smoking history with back and flank pain was found to have metastatic lung adenocarcinoma by CT and MRI. Targeted NGS sequencing discovered an EGFR L858R mutation and the patient started 80mg osimertinib treatment with excellent response of all disease sites, including brain metastases. The patient had continued response until 8.5 months after treatment initiation when a new liver lesion was found. NGS sequencing of a repeat biopsy detected the original EGFR L858R mutation as well as L718V and L718Q mutations. Afatinib treatment led to a partial response for 4.5 months, at which time disease progression occurred. Biopsy of a progressing liver lesion showed acquired EGFR T790M mutation as well as increase and decrease of L718V and L718Q mutation frequencies, respectively.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 187,
                            "name": "Osimertinib",
                            "ncit_id": "C116377",
                            "aliases": [
                                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
                                "AZD-9291",
                                "AZD9291",
                                "Mereletinib",
                                "Tagrisso"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 3253,
                        "name": "Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations.",
                        "citation": "Starrett et al., 2020, Cancer Res.",
                        "citation_id": 32193290,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/32193290",
                        "pmc_id": null,
                        "publication_date": "2020-3-19",
                        "journal": "Cancer Res.",
                        "full_journal_title": "Cancer research",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4288,
                    "name": "EID4288",
                    "description": "This study analyzed patients with non small cell lung cancer (NSCLC) who were positive for EML4-ALK fusions (ALK+) and progressed on crizotinib monotherapy. One patient was biopsied twice following crizotinib progression and once pre-treatment. This patient was a 27 year old female with one pack year who experienced partial response on crizotinib as 4th line therapy. The patient's pre-crizotinib biopsy was ALK+ and lacked the EGFR mutation. A biopsy taken after 63 days on crizotinib showed EGFR L858R mutation and lacked ALK gene rearrangement by FISH (ALK Loss). Of note, a second post-treatment biopsy (after 113 on crizotinib) showed ALK rearrangement but lacked EGFR mutation. The authors interpreted the emergence of an ALK negative tumor (first post-critozitinib biopsy) as evidence of a separate oncogenic driver (EGFR L858R).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 12,
                            "name": "Crizotinib",
                            "ncit_id": "C74061",
                            "aliases": [
                                "(R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine",
                                "2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-",
                                "MET Tyrosine Kinase Inhibitor PF-02341066",
                                "PF-02341066",
                                "PF-2341066",
                                "Xalkori"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "RESISTANCE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 507,
                        "name": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
                        "citation": "Doebele et al., 2012, Clin. Cancer Res.",
                        "citation_id": 22235099,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/22235099",
                        "pmc_id": "PMC3311875",
                        "publication_date": "2012-3-1",
                        "journal": "Clin. Cancer Res.",
                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2632,
                    "name": "EID2632",
                    "description": "In a phase II trial for bronchioloalveolar carcinoma (BAC, or in situ pulmonary adenocarcinoma), EGFR exons 18-24 were analyzed in 7 patients who had shown a partial response to erlotinib. Two patients had the del L858R mutation. One patient was a male former smoker who demonstrated response for 3 months with overall survival of 3.5 months, and the other patient was a female never smoker who had response for 6 months and overall survival of 17+ months as the patient was alive at study end.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1509,
                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
                        "citation_id": 15329413,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
                        "pmc_id": "PMC516528",
                        "publication_date": "2004-9-7",
                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2624,
                    "name": "EID2624",
                    "description": "Mutational profiling was performed on EGFR exons 18-24 from a group of 10 retrospectively chosen patients who had shown partial response or clinical improvement in response to gefitinib. Of 7 tumors with EGFR mutations, 1 was L858R. The patient was a female former smoker who had lung adenocarcinoma histology, and demonstrated response for 5 months, with overall survival 8 months.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 1,
                    "evidence_level": "C",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1509,
                        "name": "EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.",
                        "citation": "Pao et al., 2004, Proc. Natl. Acad. Sci. U.S.A.",
                        "citation_id": 15329413,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15329413",
                        "pmc_id": "PMC516528",
                        "publication_date": "2004-9-7",
                        "journal": "Proc. Natl. Acad. Sci. U.S.A.",
                        "full_journal_title": "Proceedings of the National Academy of Sciences of the United States of America",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4287,
                    "name": "EID4287",
                    "description": "In an in vitro study, CHO and NCI-H3255 cells expressing EGFR L858R mutation were associated with sensitivity to erlotinib treatment. Sensitivity was determined by assessing cell density.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": null,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2070,
                        "name": "Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.",
                        "citation": "Ray et al., 2016, Oncotarget",
                        "citation_id": 27612423,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27612423",
                        "pmc_id": "PMC5356576",
                        "publication_date": "2016-10-18",
                        "journal": "Oncotarget",
                        "full_journal_title": "Oncotarget",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 276,
                    "name": "EID276",
                    "description": "Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        }
                    ],
                    "rating": 4,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 181,
                        "name": "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.",
                        "citation": "Paez et al., 2004, Science",
                        "citation_id": 15118125,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/15118125",
                        "pmc_id": null,
                        "publication_date": "2004-6-4",
                        "journal": "Science",
                        "full_journal_title": "Science (New York, N.Y.)",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2626,
                    "name": "EID2626",
                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to lapatinib (IC50: 63nM vs. 534nM) compared to wildtype EGFR cells.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 45,
                            "name": "Lapatinib",
                            "ncit_id": "C26653",
                            "aliases": [
                                "GSK572016",
                                "GW 2016",
                                "GW2016",
                                "GW572016"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1525,
                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
                        "citation": "Li et al., 2008, Oncogene",
                        "citation_id": 18408761,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
                        "pmc_id": "PMC2748240",
                        "publication_date": "2008-8-7",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2627,
                    "name": "EID2627",
                    "description": "In an in vitro study using NCI-H322 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to Dacomitinib (IC50: 0.007umol/L vs. >10umol/L) compared to wildtype EGFR cells or compared to reversible TKI drug gefitinib (IC50: 0.075umol/L vs. wild-type >10umol/L).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 44,
                            "name": "Dacomitinib",
                            "ncit_id": "C53398",
                            "aliases": [
                                "(2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxyquinazolin-6-yl)-4-Piperidin-1-ylbut-2-Enamide",
                                "EGFR Inhibitor PF-00299804",
                                "PF-00299804",
                                "PF-00299804-03",
                                "PF-299804",
                                "Vizimpro"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1515,
                        "name": "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.",
                        "citation": "Engelman et al., 2007, Cancer Res.",
                        "citation_id": 18089823,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18089823",
                        "pmc_id": null,
                        "publication_date": "2007-12-15",
                        "journal": "Cancer Res.",
                        "full_journal_title": "Cancer research",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2628,
                    "name": "EID2628",
                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R), inhibition of cell growth was used as an assay to determine sensitivity to tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated sensitivity to neratinib (IC50: 0.0049 \u03bcmol/L) compared to EGFRwt A549 cells (IC50 > 1 \u03bcmol/L).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 52,
                            "name": "Neratinib",
                            "ncit_id": "C49094",
                            "aliases": [
                                "(2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide",
                                "2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-",
                                "HKI 272",
                                "HKI-272",
                                "PB 272",
                                "PB-272"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1526,
                        "name": "Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.",
                        "citation": "Shimamura et al., 2006, Cancer Res.",
                        "citation_id": 16818618,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/16818618",
                        "pmc_id": null,
                        "publication_date": "2006-7-1",
                        "journal": "Cancer Res.",
                        "full_journal_title": "Cancer research",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2631,
                    "name": "EID2631",
                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to canertinib (IC50: 1nM vs. 198nM) compared to wildtype EGFR cells.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 465,
                            "name": "Canertinib",
                            "ncit_id": "C77588",
                            "aliases": [
                                "2-propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-",
                                "N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1525,
                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
                        "citation": "Li et al., 2008, Oncogene",
                        "citation_id": 18408761,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
                        "pmc_id": "PMC2748240",
                        "publication_date": "2008-8-7",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 3811,
                    "name": "EID3811",
                    "description": "EGFR L858R was expressed in Ba/F3 cells which do not contain endogenous EGFR, and conferred growth factor independance to the cells. Cells were plated and treated with 1st generation EGFR inhibitors Gefitinib, Erlotinib, or the the tool compound AEE788, and IC50 values were measured. L858R EGFR cells had very low IC50 nmol/L values for all three inhibitors in comparison to other constructs (Gefitinib=12, Erlotinib=6, AEE788=6), indicating sensitivity to all three constructs.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": 162,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        },
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        },
                        {
                            "id": 90,
                            "name": "Multikinase Inhibitor AEE788",
                            "ncit_id": "C48369",
                            "aliases": [
                                "AEE 788",
                                "AEE-788",
                                "AEE788"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": "SUBSTITUTES",
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1528,
                        "name": "Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.",
                        "citation": "Kancha et al., 2009, Clin. Cancer Res.",
                        "citation_id": 19147750,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/19147750",
                        "pmc_id": null,
                        "publication_date": "2009-1-15",
                        "journal": "Clin. Cancer Res.",
                        "full_journal_title": "Clinical cancer research : an official journal of the American Association for Cancer Research",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4265,
                    "name": "EID4265",
                    "description": "MCF-7 cells were transduced with YFP tagged EGFR with E746_A750delELREA mutation, or YFP EGFR wildtype, and stained for ectopic YFP EGFR and phospho-Akt as a readout for EGFR pathway activity. Increased p-Akt stain was seen with ectopic mutant EGFR over wildtype cells. Parallel erlotinib incubations of cells with wildtype EGFR induced recompartmentalization of ectopic EGFR protien only at high concentration (10uM). Addition of erlotinib to mutant EGFR cell incubations reduced p-Akt signal and induced recompartmentalization of ectopic EGFR protien at considerably lower conecntration (100 nM) erlotinib.  These results indicate the EGFR L858R variant as a growth pathway driver targetable by erlotinib.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": 162,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1991,
                        "name": "Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.",
                        "citation": "de Gunst et al., 2007, Mol. Cancer",
                        "citation_id": 17877814,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17877814",
                        "pmc_id": "PMC2064929",
                        "publication_date": "2007-9-18",
                        "journal": "Mol. Cancer",
                        "full_journal_title": "Molecular cancer",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4286,
                    "name": "EID4286",
                    "description": "In an in vitro study, Ba/F3 and NCI-H3255 cell lines expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment (IC50=0.006 and 0.068 \u00b5M). Sensitivity was determined by assessing cell proliferation, EGFR, AKT and ERK phosphorylation, levels of BIM (a marker of EGFR TKI-induced cell killing) and cell viability.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1230,
                        "name": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
                        "citation": "Yasuda et al., 2013, Sci Transl Med",
                        "citation_id": 24353160,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24353160",
                        "pmc_id": "PMC3954775",
                        "publication_date": "2013-12-18",
                        "journal": "Sci Transl Med",
                        "full_journal_title": "Science translational medicine",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4292,
                    "name": "EID4292",
                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R did not show sensitivity to cetuximab treatment, while cells expressing EGFR-RAD51 fusion were sensitive. Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation and EGFR auto-phosphorylation.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 16,
                            "name": "Cetuximab",
                            "ncit_id": "C1723",
                            "aliases": [
                                "Cetuximab Biosimilar CDP-1",
                                "Cetuximab Biosimilar CMAB009",
                                "Cetuximab Biosimilar KL 140",
                                "Chimeric Anti-EGFR Monoclonal Antibody",
                                "Chimeric MoAb C225",
                                "Chimeric Monoclonal Antibody C225",
                                "Erbitux",
                                "IMC-C225"
                            ]
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "DOES_NOT_SUPPORT",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2086,
                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                        "citation": "Konduri et al., 2016, Cancer Discov",
                        "citation_id": 27102076,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
                        "pmc_id": "PMC4893907",
                        "publication_date": "2016",
                        "journal": "Cancer Discov",
                        "full_journal_title": "Cancer discovery",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4295,
                    "name": "EID4295",
                    "description": "In an in vitro study, a Ba/F3 cell line expressing EGFR L858R demonstrated increased sensitivity to erlotinib treatment, compared to Ba/F3 cells expressing EGFR wild-type. Variant function was assessed by EGFR auto-phosphorylation. Sensitivity was assessed by cell viability assay using stable transfection of each variant and increasing concentrations of erlotinib (0\u201310 uM).",
                    "disease": {
                        "id": 695,
                        "name": "High Grade Glioma",
                        "display_name": "High Grade Glioma",
                        "doid": 3070,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3070"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1608,
                        "name": "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.",
                        "citation": "Lee et al., 2006, PLoS Med.",
                        "citation_id": 17177598,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/17177598",
                        "pmc_id": "PMC1702556",
                        "publication_date": "2006-12",
                        "journal": "PLoS Med.",
                        "full_journal_title": "PLoS medicine",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 5922,
                    "name": "EID5922",
                    "description": "In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after EGF treatment over wildtype EGFR \n expressing cells. Cells expressing mutant EGFR also showed increased sensitivity to erlotinib treatment compared to cells expressing EGFR wild-type. Sensitivity was determined by assessing EGFR auto-phosphorylation.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": 162,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 3,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "submitted",
                    "type": "evidence",
                    "source": {
                        "id": 2081,
                        "name": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.",
                        "citation": "Foster et al., 2010, World J Surg Oncol",
                        "citation_id": 20942962,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/20942962",
                        "pmc_id": "PMC2970593",
                        "publication_date": "2010-10-13",
                        "journal": "World J Surg Oncol",
                        "full_journal_title": "World journal of surgical oncology",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 968,
                    "name": "EID968",
                    "description": "Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare the sensitivity of multiple EGFR mutations to EGFR-TKIs the authors also generated multiple EGFR transduced Ba/F3 stable cell lines and evaluated sensitivity to EGFR-TKIs by MTS assay.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 669,
                        "name": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
                        "citation": "Hirano et al., 2015, Oncotarget",
                        "citation_id": 26515464,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
                        "pmc_id": "PMC4770737",
                        "publication_date": "2015-11-17",
                        "journal": "Oncotarget",
                        "full_journal_title": "Oncotarget",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2629,
                    "name": "EID2629",
                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to irreversible tyrosine kinase inhibitor (TKI) drugs. Cells with an EGFR L858R mutation demonstrated an improved response to afatinib (IC50: 0.7nM vs. 60nM) compared to wildtype EGFR cells.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1525,
                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
                        "citation": "Li et al., 2008, Oncogene",
                        "citation_id": 18408761,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
                        "pmc_id": "PMC2748240",
                        "publication_date": "2008-8-7",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4284,
                    "name": "EID4284",
                    "description": "In an in vitro study using NCI-H1666 cells (wildtype EGFR) and NCI-H3255 cells (EGFR-L858R), inhibition of cell growth was used as an assay to determine sensitivity to reversible tyrosine kinase inhibitor drugs. Cells with an EGFR L858R mutation demonstrated an improved response to erlotinib (IC50: 40nM vs. 110nM) compared to EGFR wild type cells.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1525,
                        "name": "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.",
                        "citation": "Li et al., 2008, Oncogene",
                        "citation_id": 18408761,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/18408761",
                        "pmc_id": "PMC2748240",
                        "publication_date": "2008-8-7",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4285,
                    "name": "EID4285",
                    "description": "In an in vitro study, a MCF-7 cell line expressing EGFR L858R mutation demonstrated sensitivity to erlotinib treatment, compared to MCF-7 cells expressing EGFR wild-type. Sensitivity was determined by assessing YFP signal-EGFR relocation.",
                    "disease": {
                        "id": 216,
                        "name": "Cancer",
                        "display_name": "Cancer",
                        "doid": 162,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:162"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 1993,
                        "name": "Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.",
                        "citation": "Harada et al., 2011, Oncogene",
                        "citation_id": 21132006,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/21132006",
                        "pmc_id": null,
                        "publication_date": "2011-4-14",
                        "journal": "Oncogene",
                        "full_journal_title": "Oncogene",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4291,
                    "name": "EID4291",
                    "description": "In an in vitro study, Ba/F3 cell line expressing EGFR L858R was associated with sensitivity to erlotinib treatment (IC50 26.9 \u00b1 12.4). Sensitivity was determined by assessing cell viability, AKT and ERK phosphorylation, and EGFR auto-phosphorylation.",
                    "disease": {
                        "id": 30,
                        "name": "Lung Adenocarcinoma",
                        "display_name": "Lung Adenocarcinoma",
                        "doid": 3910,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3910"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 2086,
                        "name": "EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.",
                        "citation": "Konduri et al., 2016, Cancer Discov",
                        "citation_id": 27102076,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/27102076",
                        "pmc_id": "PMC4893907",
                        "publication_date": "2016",
                        "journal": "Cancer Discov",
                        "full_journal_title": "Cancer discovery",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4293,
                    "name": "EID4293",
                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to erlotinib (IC50: 8 and 11 nM) compared to EGFRwt NCI-H2073 cells (IC50: 108 nM; 95%CI 52-223 nM).",
                    "disease": {
                        "id": 174,
                        "name": "Lung Small Cell Carcinoma",
                        "display_name": "Lung Small Cell Carcinoma",
                        "doid": 5409,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:5409"
                    },
                    "drugs": [
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 665,
                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
                        "citation": "Cross et al., 2014, Cancer Discov",
                        "citation_id": 24893891,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
                        "pmc_id": "PMC4315625",
                        "publication_date": "2014-9",
                        "journal": "Cancer Discov",
                        "full_journal_title": "Cancer discovery",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 4294,
                    "name": "EID4294",
                    "description": "In an in vitro study using NCI-H3255 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. NCI-H3255 cells demonstrated increased sensitivity to AZD9291 (IC50: 60 and 49 nM) compared to EGFRwt NCI-H2073 cells (IC50: 1865 nM; 95%CI 872-3988 nM). In vivo experiments with NCI-H3255 xenograft models showed drastic tumour volume reduction upon treatment with 5mg/kg/day AZD9291.",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 187,
                            "name": "Osimertinib",
                            "ncit_id": "C116377",
                            "aliases": [
                                "2-Propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-",
                                "AZD-9291",
                                "AZD9291",
                                "Mereletinib",
                                "Tagrisso"
                            ]
                        }
                    ],
                    "rating": 2,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "accepted",
                    "type": "evidence",
                    "source": {
                        "id": 665,
                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
                        "citation": "Cross et al., 2014, Cancer Discov",
                        "citation_id": 24893891,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
                        "pmc_id": "PMC4315625",
                        "publication_date": "2014-9",
                        "journal": "Cancer Discov",
                        "full_journal_title": "Cancer discovery",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                },
                {
                    "id": 2633,
                    "name": "EID2633",
                    "description": "EGFR L858R mutation has been associated with increased sensitivity to first generation EGFR tyrosine kinase inhibitors, including erlotinib and gefitinib.In an in vitro study using PC9 cells (EGFR L858R mutation), inhibition of EGFR phosphorylation was used as an assay to determine sensitivity to EGFR tyrosine kinase inhibitors. PC9 cells demonstrated an increased sensitivity to gefitinib (IC50: 11.0-12.0 nmol/L vs 61.0 nmol/L) compared to NCI-H2073 cells (EGFR wild type).",
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 427,
                            "name": "Durvalumab",
                            "ncit_id": "C103194",
                            "aliases": [
                                "Imfinzi",
                                "Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide With Human Monoclonal MEDI4736 Kappa-chain, Dimer",
                                "MEDI-4736",
                                "MEDI4736"
                            ]
                        }
                    ],
                    "rating": 1,
                    "evidence_level": "D",
                    "evidence_type": "PREDICTIVE",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "evidence_direction": "SUPPORTS",
                    "variant_origin": "SOMATIC",
                    "drug_interaction_type": null,
                    "status": "rejected",
                    "type": "evidence",
                    "source": {
                        "id": 665,
                        "name": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
                        "citation": "Cross et al., 2014, Cancer Discov",
                        "citation_id": 24893891,
                        "source_type": "PUBMED",
                        "asco_abstract_id": null,
                        "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/24893891",
                        "pmc_id": "PMC4315625",
                        "publication_date": "2014-9",
                        "journal": "Cancer Discov",
                        "full_journal_title": "Cancer discovery",
                        "clinical_trials": []
                    },
                    "variant_id": 33,
                    "phenotypes": []
                }
            ],
            "variant_groups": [],
            "assertions": [
                {
                    "id": 5,
                    "type": "assertion",
                    "name": "AID5",
                    "summary": "Non-small cell lung cancer with EGFR L858R mutation is sensitive to erlotininb or gefitinib.",
                    "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitors erlotinib and gefitinib are associated with improved progression free survival over chemotherapy in EGFR L858R patients. NCCN guidelines recommend (category 1) erlotinib and gefitinib for NSCLC with sensitizing EGFR mutations, along with afatinib and osimertinib.",
                    "gene_id": 19,
                    "variant_id": 33,
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 14,
                            "name": "Gefitinib",
                            "ncit_id": "C1855",
                            "aliases": [
                                "4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline",
                                "Iressa",
                                "N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholin) Propoxy]-4-quinazolinamine",
                                "ZD 1839",
                                "ZD1839"
                            ]
                        },
                        {
                            "id": 15,
                            "name": "Erlotinib",
                            "ncit_id": "C65530",
                            "aliases": []
                        }
                    ],
                    "evidence_type": "PREDICTIVE",
                    "evidence_direction": "SUPPORTS",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "fda_regulatory_approval": true,
                    "status": "accepted"
                },
                {
                    "id": 6,
                    "type": "assertion",
                    "name": "AID6",
                    "summary": "EGFR L858R positive NSCLC is sensitive to afatinib.",
                    "description": "L858R is among the most common sensitizing EGFR mutations in NSCLC, and is assessed via DNA mutational analysis, including Sanger sequencing and next generation sequencing methods. Tyrosine kinase inhibitor afatinib is FDA approved, and is recommended (category 1) by NCCN guidelines along with erlotinib, gefitinib and osimertinib as first line systemic therapy in NSCLC with sensitizing EGFR mutation.",
                    "gene_id": 19,
                    "variant_id": 33,
                    "disease": {
                        "id": 8,
                        "name": "Lung Non-small Cell Carcinoma",
                        "display_name": "Lung Non-small Cell Carcinoma",
                        "doid": 3908,
                        "disease_url": "https://www.disease-ontology.org/?id=DOID:3908"
                    },
                    "drugs": [
                        {
                            "id": 146,
                            "name": "Afatinib",
                            "ncit_id": "C66940",
                            "aliases": [
                                "(2e)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3s)-Oxolan-3-yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)But-2-Enamide",
                                "BIBW 2992",
                                "BIBW2992"
                            ]
                        }
                    ],
                    "evidence_type": "PREDICTIVE",
                    "evidence_direction": "SUPPORTS",
                    "clinical_significance": "SENSITIVITYRESPONSE",
                    "fda_regulatory_approval": true,
                    "status": "accepted"
                }
            ],
            "variant_aliases": [
                "LEU858ARG",
                "RS121434568"
            ],
            "hgvs_expressions": [
                "NC_000007.13:g.55259515T>G",
                "NM_005228.4:c.2573T>G",
                "ENST00000275493.2:c.2573T>G",
                "NP_005219.2:p.Leu858Arg"
            ],
            "clinvar_entries": [
                "16609",
                "376282",
                "376280"
            ],
            "allele_registry_id": "CA126713"
        }
    ]
}